8-K: Xencor Announces New Autoimmune Programs and Provides Updates on Oncology Clinical Trials

Xencor is expanding its pipeline with new autoimmune disease programs and reporting encouraging initial data from ongoing oncology clinical trials.

Summary

• Xencor has announced new programs focused on autoimmune diseases, including plamotamab (CD20 x CD3), XmAb657 (CD19 x CD3), XmAb942 (Xtend TL1A), and a XmAb TL1A x IL-23 program.
• The company is also providing updates on its oncology programs, XmAb819 (ENPP3 x CD3) and XmAb808 (B7-H3 x CD28), which are in Phase 1 dose-escalation studies.
• XmAb819 has shown initial anti-tumor activity, including RECIST responses, in patients with advanced clear cell renal cell carcinoma (ccRCC).
• XmAb808 has demonstrated PSA declines in patients with metastatic castration-resistant prostate cancer (mCRPC) during a monotherapy run-in period.
• Xencor plans to initiate a Phase 1b/2a study for plamotamab in multi-drug resistant rheumatoid arthritis (MDR-RA) in the first half of 2025.
• A first-in-human study for XmAb657 is planned for the second half of 2025.
• The first-in-human study for XmAb942 is anticipated to begin in the fourth quarter of 2024, with interim data expected in the first half of 2025.
• Xencor anticipates initiating first-in-human studies for the XmAb TL1A x IL-23 program during 2026.
• The company has a strong financial position with $585 million in cash, cash equivalents, and marketable debt as of June 30, 2024, updated on August 5, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with new programs and encouraging early clinical data. The company's strong financial position and focus on protein engineering are also positive indicators. However, the early stage of the programs and the inherent risks of drug development temper the overall sentiment.

Positives

• Xencor is expanding its pipeline into autoimmune diseases with multiple new programs.
• Initial clinical data for XmAb819 in ccRCC shows encouraging anti-tumor activity.
• XmAb808 has demonstrated PSA declines in mCRPC patients, indicating potential biologic activity.
• Plamotamab has shown favorable tolerability and comparable efficacy in prior studies, supporting its use in autoimmune diseases.
• XmAb657 has demonstrated deep and durable B-cell depletion in preclinical studies.
• XmAb942 has a long half-life, potentially supporting less frequent dosing.
• Xencor has a strong financial position to support its clinical programs.

Negatives

• The clinical programs are still in early stages, with many studies yet to begin or in dose escalation.
• The company is relying on cross-trial comparisons for plamotamab, which may not be directly comparable.
• The timelines for the autoimmune programs are relatively long, with studies not expected to start until 2025 or 2026.
• There is no mention of any specific commercialization plans or timelines.

Risks

• Clinical trials may not be successful, and the drugs may not receive regulatory approval.
• There are risks associated with the development of bispecific antibodies, including potential safety issues.
• The company is reliant on third parties for development efforts.
• Changes in the competitive landscape could impact the success of Xencor's programs.
• There are potential delays in development timelines.

Future Outlook

Xencor plans to advance its clinical programs, including dose escalation for XmAb819 and XmAb808, and initiate new studies for its autoimmune programs. The company anticipates reaching target dose levels for XmAb819 and XmAb808 by year-end and providing clinical updates in the first half of 2025. First-in-human studies for XmAb942 are expected to begin in Q4 2024, with interim data in the first half of 2025. The company also plans to initiate first-in-human studies for the XmAb TL1A x IL-23 program in 2026.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that the company's clinical pipeline offers a balance of opportunities to deliver novel treatment options.
• He also mentioned that the foundation of their portfolio is world-class protein engineering, using their XmAb platforms to solve complex engineering problems.
• He emphasized the goal to leverage protein engineering strengths and reduce exposure to biological uncertainties to increase opportunities for clinical success.

Industry Context

The announcement reflects a growing trend in the biopharmaceutical industry towards developing bispecific antibodies for both oncology and autoimmune diseases. The focus on T-cell engagers and dual-targeting approaches aligns with current research and development efforts in these therapeutic areas. The company is also leveraging its proprietary XmAb platform, which is a competitive advantage in the industry.

Comparison to Industry Standards

• Xencor's approach to bispecific antibody development is similar to that of other companies in the industry, such as Roche and Janssen, who are also developing bispecific antibodies for autoimmune diseases.
• The company's Xtend Fc technology for half-life extension is comparable to other technologies like YTE, but Xencor claims superior or comparable performance.
• The company is targeting similar indications as other companies, such as rheumatoid arthritis and inflammatory bowel disease, but is using its own proprietary technology and drug candidates.
• The company is using a 2+1 format for its bispecific antibodies, which is a common approach in the industry.
• The company is also using a combination of IV and SC dosing, which is also a common approach in the industry.
• The company is using a combination of monotherapy and combination therapy, which is also a common approach in the industry.
• The company is using a combination of dose escalation and dose expansion, which is also a common approach in the industry.
• The company is using a combination of safety and efficacy endpoints, which is also a common approach in the industry.
• The company is using a combination of biomarkers and clinical endpoints, which is also a common approach in the industry.
• The company is using a combination of preclinical and clinical data, which is also a common approach in the industry.

Stakeholder Impact

• Shareholders may see a positive impact from the expansion of the pipeline and encouraging clinical data.
• Patients with autoimmune diseases and cancer may benefit from the development of new treatment options.
• Employees may be impacted by the increased workload and the need to meet development timelines.
• Partners may be impacted by the potential for new collaborations and licensing opportunities.

Next Steps

• Xencor will continue dose escalation for XmAb819 and XmAb808.
• The company will initiate a Phase 1b/2a study for plamotamab in rheumatoid arthritis.
• A first-in-human study for XmAb657 will be initiated.
• The first-in-human study for XmAb942 will begin in Q4 2024.
• First-in-human studies for the XmAb TL1A x IL-23 program will be initiated in 2026.
• The company will present preclinical data for XmAb942 at UEG Week on October 15, 2024.

Key Dates

Keywords

XmAb, bispecific antibodies, T-cell engagers, autoimmune diseases, oncology, clinical trials, rheumatoid arthritis, inflammatory bowel disease, renal cell carcinoma, prostate cancer, ENPP3, CD3, CD20, CD19, TL1A, IL-23, B7-H3, CD28